DC vaccines primed with HLA class I-restricted WT1 peptides (WT1-DC) have been shown to be safe and feasible with few adverse reactions in patients with advanced cancers including lung, breast, stomach, biliary tract, pancreas, ovary, and high-grade glioma [21,22,23,24,25,26,27,28]. Here, WT1 is linked to central nervous system cancer.